Defining inflammatory status in patients with ACS and in those with coronary atherosclerosis is becoming paramount to the efficient risk assessment and appropriate treatment of patients. As our grasp of molecular and genetic tools improves, the ability to break down the complex pathways and modulate them as potential therapeutic targets in susceptible individuals will take hold. The implications are far reaching and hold the potential to significantly alter the way clinical medicine is practiced. Nowhere is this more relevant than in interventional cardiology. From novel devices and instruments in PCI to adjuvant therapy focused on modulating inflammation, clinical practice will evolve over time. Whether this translates into improved clinical outcomes is yet to be determined. However, what will take place is a more individualized strategy of therapy based on a more complex profile of risk, one that incorporates inflammation as a vital component.
1. Topol EJ: Simon Dack Lecture: The genomic basis of myocardial infarction. J Am Coll Cardiol 2005;46:1456-1465.
2. Ridker PM, Cushman M, Stampfer MJ, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
4. Norja S, Nuutila L, Karhunen PJ, Goebeler S: C-reactive protein in vulnerable coronary plaques. J Clin Pathol 2006, Jun 21 Epub ahead of print.
5. Ridker PM: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial. Circulation 2003;108:2292-2297.
6. Henn V, Slupsky JR, Grafe M, et al: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
7. Wagner AH, Guldenzoph B, Lienenluke B, Hecker M: CD154/ CD40-mediated expression of CD154 in endothelial cells: Consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol 2004;24:715-720.
8. Andre P, Prasad KS, Denis CV, et al: CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002;8:247-252.
9. Lutgens E, Gorelik L, Daemen MJ, et al: Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313-1316.
10. Varo N, de Lemos JA, Libby P, et al: Soluble CD40L: Risk prediction after acute coronary syndromes. Circulation 2003;108:1049-1052.
11. de Lemos JA, Zirlik A, Schonbeck U, et al: Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: Results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005;25: 2192-2196.
12. Heeschen C, Dimmeler S, Hamm CW, et al: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348:1104-1111.
13. Yokoyama S, Ikeda H, Haramaki N, et al: Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol 2005;45:1280-1286.
14. Yazici M, Demircan S, Durna K, et al: Relationship between myocardial injury and soluble P-selectin in non-ST elevation acute coronary syndromes. Circ J 2005;69:530-535.
15. Ridker PM, Buring JE, Rifai N: Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103:491-495.
16. Menon V, Lessard D, Yarzebski J, et al: Leukocytosis and adverse hospital outcomes after acute myocardial infarction. Am J Cardiol 2003;92:368-372.
17. Kirtane AJ, Bui A, Murphy SA, et al: Association of peripheral neutrophilia with adverse angiographic outcomes in ST-ele-vation myocardial infarction. Am J Cardiol 2004;93:532-536.
18. Eiserich JP, Baldus S, Brennan ML, et al: Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002;296: 2391-2394.
19. Fu X, Kassim SY, Parks WC, Heinecke JW: Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276:41279-41287.
20. Baldus S, Heeschen C, Meinertz T, et al: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-1445.
21. Brennan ML, Penn MS, Van Lente F, et al: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-1604.
22. de Nooijer R, von der Thusen JH, Verkleij CJ, et al: Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol 2004;24: 2313-2319.
23. Chalikias GK, Tziakas DN, Kaski JC, et al: Interleukin-18: Interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis 2005; 182: 135-143.
24. Blankenberg S, Rupprecht HJ, Poirier O, et al: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-1585.
25. Bayes-Genis A, Conover CA, Overgaard MT, et al: Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-1029.
26. Lund J, Qin QP, Ilva T, et al: Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003;108:1924-1926.
27. Cosin-Sales J, Christiansen M, Kaminski P, et al: Pregnancy-associated plasma protein A and its endogenous inhibitor, the pro form of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 2004;109:1724-1728.
28. Cosin-Sales J, Kaski JC, Christiansen M, et al: Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J 2005;26: 2093-2098.
29. Conti E, Carrozza C, Capoluongo E, et al: Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004; 110:2260-2265.
30. Crea F, Andreotti F: Pregnancy associated plasma protein-A and coronary atherosclerosis: Marker, friend, or foe? Eur Heart J 2005;26:2075-2076.
31. Hata N, Matsumori A, Yokoyama S, et al: Hepatocyte growth factor and cardiovascular thrombosis in patients admitted to the intensive care unit. Circ J 2004;68:645-649.
32. Zhou X, Nicoletti A, Elhage R, Hansson GK: Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000;102:2919-2922.
33. Cheng X, Liao YH, Ge H, et al: TH1/TH2 functional imbalance after acute myocardial infarction: Coronary arterial inflammation or myocardial inflammation. J Clin Immunol 2005;25:246-253.
34. Liuzzo G, Vallejo AN, Kopecky SL, et al: Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation 2001;103:1509-1514.
35. Wang L, Fan C, Topol SE, et al: Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003;302:1578-1581.
36. Helgadottir A, Manolescu A, Thorleifsson G, et al: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36: 233-239.
37. Helgadottir A, Manolescu A, Helgason A, et al: A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38:68-74.
38. Hakonarson H, Thorvaldsson S, Helgadottir A, et al: Effects of a 5-lipoxygenase-activating protein inhibitor on biomark-ers associated with risk of myocardial infarction: A randomized trial. JAMA 2005;293:2245-2256.
39. Moses JW, Leon MB, Popma JJ, et al: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
40. Stone GW, Ellis SG, Cox DA, et al: A polymer-based, pacli-taxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
41. Farb A, Weber DK, Kolodgie FD, et al: Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-2980.
42. Hong SJ, Kim MH, Ahn TH, et al: Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart 2006;92:1119-1124.
43. Simon DI, Dhen Z, Seifert P, et al: Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. J Clin Invest 2000;105: 293-300.
44. Fukuda D, Shimada K, Tanaka A, et al: Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 2004;43:18-23.
45. Turker S, Guneri S, Akdeniz B, et al: Usefulness of preproce-dural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol 2006;97:198-202.
46. Inoue T, Kato T, Uchida T, et al: Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005;46:239-245.
47. Segev A, Kassam S, Buller CE, et al:. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J 2004;25:1029-1035.
48. Zairis MN, Ambrose JA, Manousakis SJ, et al: The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002;40:1375-1382.
49. Walter DH, Fichtlscherer S, Sellwig M, et al: Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839-846.
50. Dibra A, Mehilli J, Braun S, et al: Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 2005;150:344-350.
51. Gibson CM, Karmpaliotis D, Kosmidou I, et al: Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol 2006;97:1473-1477.
52. Iakovou I, Schmidt T, Bonizzoni E, et al: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
53. Farb A, Burke AP, Kolodgie FD, Virmani R: Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-1706.
54. Farb A, Heller PF, Shroff S, et al: Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479.
55. Joner M, Finn AV, Farb A, et al: Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
56. Finn AV, Kolodgie FD, Harnek J, et al: Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-278.
57. Ray KK, Cannon CP: Pathological changes in acute coronary syndromes: The role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis 2004;18:89-101.
58. Rezaie-Majd A, Prager GW, Bucek RA, et al: Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2003;23:397-403.
59. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al: Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003;93:948-956.
60. Schwartz GG, Olsson AG, Ezekowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study—A randomized controlled trial. JAMA 2001;285:1711-1718.
62. Ridker PM, Cannon CP, Morrow D, et al: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
63. Kinlay S, Schwartz GG, Olsson AG, et al: High-dose atorvas-tatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560-1566.
64. Nissen SE, Tuzcu EM, Schoenhagen P, et al: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-1080.
65. Iwakura K, Ito H, Kawano S, et al: Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006;27:534-539.
66. Patti G, Chello M, Pasceri V, et al: Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: Results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006;48: 1560-1566.
67. Steinhubl SR, Berger PB, Mann JT 3rd, et al: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
68. Mehta SR, Yusuf S, Peters RJ, et al: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533.
69. Sabatine MS, Cannon CP, Gibson CM, et al: Effect of clopi-dogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 2005;294:1224-1232.
70. Xiao Z, Theroux P: Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004;43:1982-1988.
71. Klinkhardt U, Bauersachs R, Adams J, et al: Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003;73:232-241.
72. Vivekananthan DP, Bhatt DL, Chew DP, et al: Effect of clopi-dogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004;94:358-360.
73. Quinn MJ, Bhatt DL, Zidar F, et al: Effect of clopidogrel pre-treatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004;93:679-684.
74. Nienhuis MB, Ottervanger JP, Miedema K, et al: Pre-treat-ment with clopidogrel and postprocedure troponin elevation after elective percutaneous coronary intervention. Thromb Haemost 2006;95:337-340.
75. Patti G, Colonna G, Pasceri V, et al: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005;111:2099-2106.
76. Kandzari DE, Berger PB, Kastrati A, et al: Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004;44:2133-2136.
77. Kastrati A, Mehilli J, Schuhlen H, et al: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350: 232-238.
78. Kastrati A, Mehilli J, Neumann FJ, et al: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-1538.
79. Furman MI, Krueger LA, Linden MD, et al: GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 2005;3:312-320.
80. Keating FK, Dauerman HL, Whitaker DA, et al: The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 2005;16:401-405.
81. Keating FK, Dauerman HL, Whitaker DA, et al: Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006;118:361-369.
82. Versaci F, Gaspardone A, Tomai F, et al: Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS study). J Am Coll Cardiol 2002;40:1935-1942.
83. Lim MY, Wang H, Kapoun AM, et al: P38 inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J Mol Cell Cardiol 2004;37:1111-1114.
84. Nahrendorf M, Jaffer FA, Kelly KA, et al: Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006;114: 1504-1511.
85. Greenbaum AB, Grines CL, Bittl JA, et al: Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006;151:689 e1-689 e10.
86. Monraats PS, Rana JS, Nierman MC, et al: Lipoprotein lipase gene polymorphisms and the risk of target vessel revascular-ization after percutaneous coronary intervention. J Am Coll Cardiol 2005;46:1093-1100.
87. Wijpkema JS, van Haelst PL, Monraats PS, et al: Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. Pharmacogenet Genomics 2006;16:331-337.
88. Monraats PS, Pires NM, Agema WR, et al: Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005;112:2417-2425.
89. Niessner A, Marculescu R, Kvakan H, et al: Fractalkine receptor polymorphisms V2491 and T280M as genetic risk factors for restenosis. Thromb Haemost 2005;94:1251-1256.
90. Hamann L, Gomma A, Schroder NW, et al: A frequent tolllike receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. J Mol Med 2005;83:478-485.
91. Tiroch K, von Beckerath N, Koch W, et al: Interferon-gamma and interferon-gamma receptor 1 and 2 gene polymorphisms and restenosis following coronary stenting. Atherosclerosis 2005;182:145-151.
92. Koch W, Mehilli J, Pfeufer A, et al: Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting. J Lipid Res 2004;45:2221-2226.
93. Gaspardone A, Versaci F, Tomai F, et al: C-reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol 2006;97:1311-1316.
94. Dibra A, Ndrepepa G, Mehilli J, et al: Comparison of C-reac-tive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. Am J Cardiol 2005;95:1238-1240.
95. de la Torre-Hernandez JM, Sainz-Laso F, Burgos V, et al: Comparison of C-reactive protein levels after coronary stenting with bare metal versus sirolimus-eluting stents. Am J Cardiol 2005;95:748-751.
96. Gogo PB Jr, Schneider DJ, Watkins MW, et al: Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis 2005;19:87-92.
97. Kim JY, Ko YG, Shim CY, et al: Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005;96:1384-1388.
98. Chan AW, Bhatt DL, Chew DP, et al: Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-1756.
99. Chan AW, Bhatt DL, Chew DP, et al: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-696.
100. Hong YJ, Jeong MH, Hyun DW, et al: Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005;95:619-622.
101. Gaspardone A, Versaci F, Proietti I, et al: Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. Am J Cardiol 2002;90:786-789.
102. Schomig A, Mehilli J, Holle H, et al: Statin treatment following coronary artery stenting and one-year survival. J Am Coll Cardiol 2002;40:854-861.
103. Saia F, de Feyter P, Serruys PW, et al: Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. Am J Cardiol 2004;93:92-95.
104. Pasceri V, Patti G, Nusca A, et al: Randomized trial of ator-vastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-678.
105. Chang SM, Yazbek N, Lakkis NM: Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004;62:193-197.
106. Lee CH, de Feyter P, Serruys PW, et al: Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: Results from the Lescol Intervention Prevention Study (LIPS). Heart 2004; 90:1156-1161.
107. Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Optimal timing for the initiation of pre-treatment with 300 mg clopi-dogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006;47:939-943.
108. Hochholzer W, Trenk D, Frundi D, et al: Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-2564.
109. Gurbel PA, Cummings CC, Bell CR, et al: Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003;145:239-247.
Was this article helpful?